



FOR IMMEDIATE RELEASE

Toni Choueiri, M.D. Named to ACCRU Board of Directors

Respected GU cancer expert Dr. Choueiri's primary research is focused on developing novel experimental therapies and biomarkers in GU malignancies.

ACCRU News & Releases – February 2023. Academic and Community Cancer Research United (ACCRU) is pleased to announce that Toni Choueiri, M.D. has been named to ACCRU's Board of Directors.

Dr. Choueiri is a medical oncologist with a specific focus in genitourinary cancers. He joins the ACCRU board with robust leadership experience in institutional research. In addition to his role as the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), Dr. Choueiri also co-leads the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and is the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School.

"We are delighted to have Dr. Choueiri joining the ACCRU Board Director," says Dr. Tony Bekaii-Saab, Professor of Oncology at Mayo Clinic and the ACCRU Consortium Chair.

"Toni brings with him an incredible track record as a world class clinical and translational researcher. He is one of the most respected GU cancer experts around the world, and we are incredibly fortunate to have him join us."

"Innovative, nimble, translational and clinical trials can transform the lives of cancer patients," says Dr. Choueiri. "I feel this is what ACCRU is about, and I am honored to join the Board of Directors to continue this noble mission."

Dr. Choueiri's primary research is focused on developing novel experimental therapies and biomarkers in GU malignancies, including renal cell carcinoma (RCC). His research also focuses on the epidemiology, diagnosis, and treatment



FOR IMMEDIATE RELEASE

outcomes of GU cancers, especially through having co-established the International Metastatic RCC Database Consortium criteria for RCC risk stratification.

One of the principal investigators of the METEOR study, Dr. Choueiri has specifically made observations that have defined and evolved the treatment of metastatic RCC and led to the approval of several therapies such as Cabozantinib, Pazopanib, Avelumab+Axitinib, Cabozantinib+Nivolumab, and Pembrolizumab+Lenvatinib, as well as adjuvant pembrolizumab.

As one of the world's leading cancer research networks, ACCRU is at the forefront of today's most innovative research. ACCRU is a collaborative clinical research network of academic and community-based cancer centers with a goal to prevent cancer, cure cancer, and attenuate cancer-related symptoms. ACCRU's mission is to transform the lives of patients by changing the standard of care. The ACCRU Research Coordinating Center is based at Mayo Clinic Cancer Center.

For more information contact Kirsten Tangeros at kirsten@czstrategy.com

###